At the news
? BULLISHIMPACT 7/10 8-K filed Jul 20, 2026 at 09:03 ET
Tempus AI announced a definitive agreement to acquire Personalis (PSNL) for $16.25/share in a stock transaction valued at $1.5B enterprise value (net of Tempus' existing stake). The deal integrates Personalis' industry-leading MRD technology into Tempus' AI precision oncology platform, targeting a $20B MRD market. Personalis reported Q2 preliminary revenue of $22.4M and 10,384 clinical tests (+33% QoQ). Closing expected late 2026/early 2027, subject to Personalis shareholder approval and regulatory clearances.
- Acquisition price: $16.25 per Personalis share, total enterprise value $1.5B net of Tempus' existing ownership
- Consideration: 100% stock with Tempus option to pay cash up to 50%; floating exchange ratio subject to max 0.3356
- Closing expected late 2026 or early 2027; Personalis can terminate if TEM stock falls below $46.00
- Personalis Q2 preliminary revenue $22.4M, 10,384 clinical tests (+33% QoQ)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access